Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS) Vaccine Vector to Protect Against SARS-CoV-2 Infection:
World’s first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation Ongoing durable complete responses ranging from 8 to 11 months observed in TNBC patients who failed standard of care Disease control rate of 78% and
Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone Metastatic pancreatic cancer patient treated with PD-L1 t-haNK
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Apr. 29, 2020-- NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc. , today announced that Patrick Soon-Shiong , M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at
EL SEGUNDO, Calif. ,--(BUSINESS WIRE)--May 26, 2020-- NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc. , today announced that Patrick Soon-Shiong , M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET .
The NANT Cancer Vaccine, the First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic, T Cell and NK Cell Activation Personalized Molecular Informed Therapy with NantHealth's GPS Cancer as the Complementary Diagnostic for All Tumor Types A Cancer
by Jen Hodson | Apr 4, 2017 | Press Releases | Culver City and San Diego, CA April 4, 2017 - NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc . announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc .
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 12, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
Promising Clinically Meaningful Responses Seen Including a Radiological Complete Response in Early Data Analysis Presented at the 31st Annual Meeting of the Society for Immunotherapy of Cancer CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 14, 2016-- NantKwest Inc.